TirzepatideRanked
Find my match
Price index re-read 2026-10-15 NexLife prices 2026-11-06 Methodology v4.1 Programs priced 28 Corrections open log

Trial review

SURMOUNT-5: Tirzepatide vs Semaglutide Head to Head

Tirzepatide versus semaglutide, head to head

Researched By Dr. Parmis · Medical Researcher · Western University of Health Sciences

Medically Reviewed By Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)

Last medically reviewed: · This page is informational and does not constitute medical advice.

Direct answer

SURMOUNT-5 was a phase 3b, randomised, open-label, active-controlled head-to-head funded by Eli Lilly and Company. Least-squares mean weight change of −20.2% with tirzepatide versus −13.7% with semaglutide (P<0.001); −22.8 kg versus −15.0 kg; waist circumference −18.4 cm versus −13.0 cm. That figure belongs to the population, dose, comparator and 72 weeks shown below, and describes a group average under trial conditions rather than a prediction for any individual.

Answer last reviewed: Evidence:
SURMOUNT-5 at a glanceVerified
Data table
DesignPhase 3b, randomised, open-label, active-controlled head-to-head
PopulationAdults with obesity but without type 2 diabetes; BMI 30 or above, or 27 or above with at least one obesity-related complication. 32 sites in the United States and Puerto Rico, April 2023 to November 2024
Sample size751 randomised 1:1
InterventionTirzepatide once weekly at maximum tolerated dose
ComparatorSemaglutide once weekly at maximum tolerated dose, 1.7 mg or 2.4 mg
Duration72 weeks
Primary endpointPercentage change in body weight from baseline at week 72
Main resultLeast-squares mean weight change of −20.2% with tirzepatide versus −13.7% with semaglutide (P<0.001); −22.8 kg versus −15.0 kg; waist circumference −18.4 cm versus −13.0 cm
NCT NCT05822830 · DOI 10.1056/NEJMoa2416394Last source check: 2026-07-24
How to read SURMOUNT-5 without over-reading it
1Who was eligibleAdults with obesity but without type 2 diabetes; BMI 30 or above, or 27 or above with at2What they receivedTirzepatide once weekly at maximum tolerated dose3What it was compared againstSemaglutide once weekly at maximum tolerated dose, 1.7 mg or 2.4 mg4For how long72 weeks5What was measured firstPercentage change in body weight from baseline at week 726What the group average wasLeast-squares mean weight change of −20.2% with tirzepatide versus −13.7% with semagluti7What it does not tell youA group average is not a prediction for any individual reader.
Show this figure as a table
Data table
StepStageWhat happens
1Who was eligibleAdults with obesity but without type 2 diabetes; BMI 30 or above, or 27 or above with at least one obesity-related complication. 32 sites in the United States and Puerto Rico, April 2023 to November 2024
2What they receivedTirzepatide once weekly at maximum tolerated dose
3What it was compared againstSemaglutide once weekly at maximum tolerated dose, 1.7 mg or 2.4 mg
4For how long72 weeks
5What was measured firstPercentage change in body weight from baseline at week 72
6What the group average wasLeast-squares mean weight change of −20.2% with tirzepatide versus −13.7% with semaglutide (P<0.001); −22.8 kg versus −15.0 kg; waist circumference −18.4 cm versus −13.0 cm
7What it does not tell youA group average is not a prediction for any individual reader.
Strip any step and the result stops meaning what the trial found.
Primary results, from the peer-reviewed publicationNew England Journal of Medicine 2025;393(1):26-36
Tirzepatide, % weight change20%Semaglutide, % weight change14%
Show this figure as a table
Data table
ItemWeight changeEvidence
Tirzepatide, % weight change20%Verified
Semaglutide, % weight change14%Verified
Group means under trial conditions. Not a prediction for any individual reader.
What this trial can and cannot tell you
What this trial can and cannot tell you
QuestionPosition
Average effect in the studied populationReported once captured
Your individual outcomeNot predicted by any trial
Effect of a compounded preparationNot studied here
Effect at doses outside the protocolNot studied here
Effect after stoppingOnly if the trial included a withdrawal phase
Long-term safety beyond the trialOutside the observation window

Who was studied

SURMOUNT-5 randomised 751 adults with obesity and without type 2 diabetes at 32 sites in the United States and Puerto Rico. To join, you needed a BMI of 30 or more, or 27 or more with at least one weight-related condition: high blood pressure, abnormal blood lipids, obstructive sleep apnea or cardiovascular disease. You also needed at least one past diet attempt that had not worked.

Who was not studied:

  • People with diabetes of any type.
  • Anyone whose weight had changed by more than 5 kg in the three months before the trial.
  • People with a history of pancreatitis, or a personal or family history of medullary thyroid carcinoma or MEN-2.
  • People with significant active or unstable depression, or another severe psychiatric disorder, in the previous two years.
  • People outside the US and Puerto Rico, and anyone under 18.

Source: the trial's ClinicalTrials.gov record (NCT05822830), read November 9, 2026.

What was given, and what it was compared against

SURMOUNT-5 compared two active drugs. It had no placebo arm, and it was open-label: participants and investigators knew who was taking which medicine.

  • Tirzepatide started at 2.5 mg once a week for four weeks, then rose by 2.5 mg every four weeks toward 15 mg. People stayed on their maximum tolerated dose, either 10 mg or 15 mg.
  • Semaglutide started at 0.25 mg once a week, then stepped through 0.5, 1.0 and 1.7 mg to 2.4 mg at four-week intervals. The maximum tolerated dose was 1.7 mg or 2.4 mg.
  • Both were injected under the skin. Participants were randomised 1:1 (375 to tirzepatide, 376 to semaglutide) and treated for 72 weeks.

The trial tested the manufacturers' products. No compounded preparation of either drug was involved, and the results do not describe one.

Sources: Aronne et al., NEJM 2025;393:26-36 (abstract, read via PubMed, PMID 40353578) and the ClinicalTrials.gov arm descriptions, both read November 9, 2026.

Results

Primary endpoint: percent change in body weight from the start to week 72. It was −20.2% with tirzepatide (95% CI −21.4 to −19.1) and −13.7% with semaglutide (95% CI −14.9 to −12.6), P<0.001. These are least-squares means from the NEJM abstract, which does not name the estimand.

Secondary endpoints (ClinicalTrials.gov results, observed values among participants with week-72 data):

Outcome at week 72TirzepatideSemaglutide
Lost at least 10%87.7%66.7%
Lost at least 15%71.7%45.0%
Lost at least 20%55.0%31.1%
Lost at least 25%36.5%18.6%
Lost at least 30%23.0%8.2%
Waist circumference−18.4 cm−13.0 cm
BMI−8.5 kg/m²−6.0 kg/m²

A further secondary analysis compared 15 mg tirzepatide with 2.4 mg semaglutide as if everyone had stayed on treatment at the top dose. It gave −21.8% and −15.4%. That on-treatment estimate answers a different question from the primary result. We could not open the full paper on November 9, 2026 to confirm the change in kilograms, so we do not state it here.

Adverse events and discontinuations

From the ClinicalTrials.gov results record (start to week 72; 374 people on tirzepatide and 376 on semaglutide who received at least one dose):

EventTirzepatideSemaglutide
Serious adverse events18 (4.8%)13 (3.5%)
Deaths00
Nausea163 (43.6%)167 (44.4%)
Constipation101 (27.0%)107 (28.5%)
Diarrhoea88 (23.5%)88 (23.4%)
Vomiting56 (15.0%)80 (21.3%)

The NEJM abstract says the most common events in both groups were gastrointestinal, mostly mild to moderate, and mostly during dose escalation.

Discontinuation. 319 of 375 (85.1%) on tirzepatide and 319 of 376 (84.8%) on semaglutide completed the study. Six people in each group left the study because of an adverse event. These are study withdrawals. The paper also reports how many people stopped the drug because of side effects, but we could not open it on November 9, 2026, so we do not state that figure.

Limitations

  • Funding. Eli Lilly, which makes tirzepatide, funded the trial, and several authors are Lilly employees.
  • Open-label design. Everyone knew which drug they were taking. That can affect behaviour, side-effect reporting and dropout. Weight is an objective measure, which limits the problem but does not remove it.
  • Dose design. Each group used its maximum tolerated dose, so not everyone was on the top dose of either drug.
  • Dropout. About 15% of each group did not complete the study. How missing data were handled affects the size of the estimate, and the abstract does not describe it.
  • Population. No one had diabetes, all sites were in the US and Puerto Rico, and the exclusions were broad. The result may not hold for people outside those limits.
  • Duration and endpoints. Seventy-two weeks of weight and waist measures. The trial says nothing about heart attacks, strokes or deaths, or about what happens after stopping.

How this should and should not be read

A fair reading: in adults with obesity and without diabetes, over 72 weeks at their highest tolerated doses, tirzepatide produced a larger average weight loss than semaglutide. The difference in the primary endpoint was 6.5 percentage points.

Common misreadings:

  • "I will lose 20% on tirzepatide." That is a group average. Just over half the tirzepatide group (55.0%) lost 20% or more, which means the rest did not.
  • "Semaglutide doesn't work." Its group averaged −13.7%, and two-thirds lost at least 10%.
  • "Compounded tirzepatide beats Wegovy." No compounded product was tested.
  • "Tirzepatide has worse side effects." Nausea, constipation and diarrhoea rates were similar, and vomiting was more common with semaglutide. In an open-label trial, treat side-effect comparisons cautiously either way.
  • "Tirzepatide is better for the heart." The trial did not measure heart events.

How it compares with other trials

SURMOUNT-5 is the head-to-head trial. Most other tirzepatide and semaglutide weight trials used placebo, so their numbers do not line up with this one.

  • SURMOUNT-1 used placebo, fixed doses and 72 weeks. At 15 mg, mean weight change was −20.9% against −3.1% on placebo (treatment-regimen estimand; Jastreboff et al., NEJM 2022, abstract read November 9, 2026). The tirzepatide arm of SURMOUNT-5 landed in a similar range. But SURMOUNT-5 used maximum tolerated dosing, an active comparator, open-label treatment and US-only sites, so this is a rough consistency check, not a repeat result.
  • Semaglutide's own placebo-controlled trials (the STEP program) had different designs. Subtracting one trial's result from another's is not a fair comparison, which is why a direct trial like this one matters.
  • In type 2 diabetes, SURPASS-2 compared tirzepatide with semaglutide 1 mg on blood sugar. The population, doses and primary endpoint all differ.

Questions readers actually ask

Does this mean I would lose that much weight?

No. Trials report group averages under controlled conditions with specific eligibility criteria. Individual results vary widely, and the trial population may not resemble you.

Do these results apply to compounded tirzepatide?

Not automatically. Trials studied the approved product at studied doses. A compounded preparation at a different concentration, formulation or route has not been through those trials.

Cite this pageCC BY 4.0

Tirzepatide Ranked. “SURMOUNT-5: Tirzepatide vs Semaglutide Head to Head.” S.J Partners LLC, 2026-07-26. https://tirzepatideranked.com/research/surmount-5/

Quote the capture date beside a figure, not the date you read this page. Why.

Report an error
Comparing 0 of 4